喀什看妇科到那些医院最好喀什市无痛人流最安全的医院,博大医院看妇科怎么样,喀什男性功能障碍咋办,喀什市妇科的不要孩子费用,喀什取环要多少价钱,喀什男人割包皮都会有那些好处,喀什胎儿几个月做四维

WASHINGTON, July 13 (Xinhua) -- Human neural stem cells are capable of helping people regain learning and memory abilities lost due to radiation treatment for brain tumors, a University of California, Irvine (UCI) study suggests.Research with rats found that stem cells transplanted two days after cranial irradiation restored cognitive function, as measured in one- and four-month assessments. In contrast, irradiated rats not treated with stem cells showed no cognitive improvement."Our findings provide solid evidence that such cells can be used to reverse radiation-induced damage of healthy tissue in the brain," said Charles Limoli, a UCI radiation oncology professor.Study results will appear Friday in Cancer Research, a journal of the American Association for Cancer Research.Radiotherapy for brain tumors is limited by how well the surrounding tissue tolerates it. Patients receiving radiation at effective levels suffer varying degrees of learning and memory loss that can adversely affect their quality of life."In almost every instance, people experience severe cognitive impairment that's progressive and debilitating," Limoli said. " Pediatric cancer patients can experience a drop of up to three IQ points per year."For the UCI study, multipotent human neural stem cells were transplanted into the brains of rats that had undergone radiation treatment. They migrated throughout the hippocampus -- a region known for the growth of new neurons -- and developed into brain cells.Researchers assessed the rats one month and four months after transplantation, noting enhanced learning and memory abilities at both intervals.Additionally, they found that transplanting as few as 100,000 human neural stem cells was sufficient to improve cognition after cranial irradiation. Of cells surviving the process, about 15 percent turned into new neurons, while another 45 percent became astrocytes and oligodendrocytes -- cells that support cerebral neurons.Most notably, Limoli said, he and his colleagues discovered that about 11 percent of the engrafted cells expressed a behaviorally induced marker of learning, indicating the functional integration of those cells into memory circuits in the hippocampus."This research suggests that stem cell therapies may one day be implemented in the clinic to provide relief to patients suffering from cognitive impairments incurred as a result of their cancer treatments," Limoli said.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

MOSCOW, June 15 (Xinhua) -- Russia's Mission Control announced on Wednesday it had raised the International Space Station (ISS) by 10.2 km to 374.7 km with the help of the Europe's ATV-2 Johannes Kepler.The Mission Control conducted the correction to the ISS at 19: 55 Moscow time (1555 GMT) by the boosters of the ATV-2 Johannes Kepler. The correction had lasted for some 40 minutes.According to the Mission Control, the correction was made in line with the ISS's ballistic flight program.On June 12, the Europe's second Automated Transfer Vehicle (ATV) Johannes Kepler has conducted two similar operations, raising the ISS orbit by 19.2 km to 364.6 km.Corrections to the space station's orbit are conducted periodically before launches of Russian cargo ships and U.S. shuttles to compensate for the Earth's gravity and to safeguard successful dockings.According to the Mission Control, the ATV-2 Johannes Kepler is scheduled to undock from the ISS on June 21.

MOSCOW, Aug. 3 (Xinhua) -- Two Russian cosmonauts manually launched a mini satellite from the International Space Station ( ISS) during a six-hour spacewalk Wednesday, said the Mission Control center near Moscow.Sergei Volkov and Alexander Samokutyayev, who started the spacewalk with a 20-minute delay, found the 30-kg Kedr has lost one of its two antennas during its delivery to the ISS in January. After consulting with the Mission Control, they have decided to launch the device anyway, Interfax news agency reported.The Kedr satellite, which was made by Russian students, was created to transmit from the orbit greetings in 15 languages about the 50th anniversary of Yuri Gagarin's first space flight. It could also photograph the Earth and re-transmit information from the ISS equipment.During the spacewalk, the cosmonauts were expected to install new stream video equipment on the station's outer surface, and to take pictures holding photos of the founders of Russian space explorations, including Konstantin Tsiolkovski, Sergei Korolyov and Yuri Gagarin.

KIEV, Aug. 2 (Xinhua) -- Ukraine's regional health authority declared Tuesday a cholera epidemic in the eastern region of Donetsk had ended.All 26 people who had been treated for the disease had been discharged from hospital, the press-service of the Donetsk Regional Sanitary and Epidemiological Service said on its official website.As of this week, no new cases had been registered, the statement said.The cholera outbreak hit eastern Ukraine in late May. The disease can cause rapid dehydration and death.The outbreak was believed to be associated with fish and drinking water supplies from the Sea of Azov.